275 related articles for article (PubMed ID: 17187006)
1. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Kopecek M; Bares M; Horacek J; Mohr P
Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
[TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinemia after low dose of amisulpride.
Kopecek M; Bares M; Svarc J; Dockery C; Horácek J
Neuro Endocrinol Lett; 2004 Dec; 25(6):419-22. PubMed ID: 15665803
[TBL] [Abstract][Full Text] [Related]
3. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Holzer L; Eap CB
J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
[TBL] [Abstract][Full Text] [Related]
4. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
5. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
6. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
[TBL] [Abstract][Full Text] [Related]
7. Hyperprolactinaemia - a risperidone side-effect.
Grahovac T; Ruzić K; Medved P; Pavesić-Radonja A; Dadić-Hero E
Psychiatr Danub; 2010 Mar; 22(1):120-2. PubMed ID: 20305606
[TBL] [Abstract][Full Text] [Related]
8. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
9. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Keller R; Mongini F
Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
[TBL] [Abstract][Full Text] [Related]
10. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
13. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.
Peitl MV; Peitl V; Grahovac T; Pavlović E
Psychiatr Danub; 2010 Mar; 22(1):125-7. PubMed ID: 20305608
[TBL] [Abstract][Full Text] [Related]
14. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
15. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
Kinon BJ; Gilmore JA; Liu H; Halbreich UM
Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
[TBL] [Abstract][Full Text] [Related]
17. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
[TBL] [Abstract][Full Text] [Related]
18. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
19. Effect of risperidone on prolactinoma--a case report.
Mendhekar DN; Jiloha RC; Srivastava PK
Pharmacopsychiatry; 2004 Jan; 37(1):41-2. PubMed ID: 14750048
[TBL] [Abstract][Full Text] [Related]
20. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Masi G; Cosenza A; Mucci M
J Child Adolesc Psychopharmacol; 2001; 11(4):389-94. PubMed ID: 11838821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
